Sore Throat News and Research

RSS

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),

16 May 2014

Virtual doctors visits await regulation, grow in popularity

And recommendations on digital privacy protections for electronic health records could come as early as June.

12 May 2014

First Edition: May 9, 2014

Today's headlines include highlights from the first Senate confirmation hearing for Sylvia Mathews Burwell, President Barack Obama's pick for Health and Human Services Secretary.

9 May 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Oral and oropharyngeal cancer (cancer of the mouth and upper throat) collectively kill nearly one person every hour of every day of the year.

27 Mar 2014

Study shows only 23% of seasonal and pandemic flu caused symptoms

Around 1 in 5 of the population were infected in both recent outbreaks of seasonal flu and the 2009 H1N1 influenza pandemic, but just 23% of these infections caused symptoms, and only 17% of people were ill enough to consult their doctor.

17 Mar 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the current label of XELJANZ® (tofacitinib citrate) 5 mg tablets to include radiographic data from two Phase 3 studies, ORAL Scan (A3921044) and ORAL Start.

25 Feb 2014

URTI risk factor for chronic, recurrent otitis media

Results from a meta-analysis indicate that upper respiratory tract infection increases the odds of chronic or recurrent otitis media over sixfold.

3 Feb 2014

Duration of common pediatric respiratory infections estimated

An international research team has systematically reviewed the literature to formulate up-to-date estimates of the duration of common childhood respiratory tract infections.

24 Dec 2013

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

Generally speaking, reflux has been a major chronic issue for probably the last 40 or 50 years. When you look at the global population, depending on which country we're talking about, around 20% to 40% of individuals have reflux disease within their populations.

23 Dec 2013

College students not only bring dirty socks but also mononucleosis to home

One of the hallmarks of heading home for winter break is the enormous amounts of laundry college students bring as a welcome home present for Mom and Dad. But the dirty socks might not be the only unwelcome guest they transport home. They might also bring mononucleosis, better known as mono.

6 Dec 2013

Sore Throat News and Research

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Virtual doctors visits await regulation, grow in popularity

First Edition: May 9, 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

People urged to undergo oral cancer screenings as part of Oral Cancer Awareness Month

Study shows only 23% of seasonal and pandemic flu caused symptoms

FDA approves KALYDECO for people with cystic fibrosis

FDA approves sNDA to include radiographic data updating label of Pfizer XELJANZ for treatment of RA

URTI risk factor for chronic, recurrent otitis media

Duration of common pediatric respiratory infections estimated

Reflux disease diagnosis: an interview with Professor Peter Dettmar, Managing Director of RD Biomed Limited

College students not only bring dirty socks but also mononucleosis to home

In states not expanding Medicaid, hospitals face a squeeze as federal funds dry up

First Edition: November 11, 2013

Research roundup: Pricing and the SHOP exchange; health use in rural vs. urban areas; the health law and AIDS care

New 'clinical score' test for patients with sore throats reduces antibiotics usage nearly 30%

First generic versions of Aciphex delayed-release tablets get FDA approval for GERD treatment

Paracetamol, ibuprofen or combination of both provide no advantage for respiratory tract infections

Sore throat clinical score boosts effective antibiotic use

Luden partners with Thompson Square to celebrate "Voices Worth Hearing"

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News